2008: Spondyloarthritis: Treatment
Search
or
Browse by Day
Spondyloarthritis: Treatment
Sunday, October 26, 2008
670
Adalimumab (HUMIRA
®
) Therapy for Ankylosing Spondylitis Over 2 Years Does Not Demonstrate Inhibition of Radiographic Progression Compared With a Historical Control Group
671
Golimumab Administered Subcutaneously Every 4 Weeks In Psoriatic Arthritis Patients: 52-Week Efficacy And Safety Results Of The Randomized, Placebo-Controlled GO-REVEAL Study
672
Defining Minimal Disease Activity in Psoriatic Arthritis: a Proposed Objective Target for Treatment
673
Assessment of Clinical Efficacy in a Randomized, Double-Blind Study of Etanercept and Sulphasalazine in Patients With Ankylosing Spondylitis
674
A Randomized, Placebo-Controlled Study to Identify Biomarkers Associated With Active Treatment in Psoriatic Arthritis: Effects of Adalimumab Treatment on Synovial Biomarkers
675
Adalimumab (HUMIRA
®
) Improves Inflammatory Bowel Disease (IBD) and Psoriasis (Ps) and Prevents Anterior Uveitis (AU) Flares in Patients With Ankylosing Spondylitis (AS)
See more of:
ACR Abstract Submission ACR Concurrent Abstract Session
<< Previous Session Level
|
Next Session Level >>
![[ Visit Client Website ]](images/banner.gif)